1[1]Lockridge O.Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine.Pharmacol Ther,1990,47(1):35 -60
2[2]Viby -Mogensen J.Succinylcholine neuromuscular blockade in subjects heterozygous for abnormal plasma cholinesterase.Anesthesiology.1981 Sep,55(3):231 -235
3[3]Salvidio E,Pannacciulli I,Tizianello A,Ajmar F.Nature of hemolytic crises and the fate of G6PD deficient,drag-damaged erythrocytes in Sardinians.N Engl J Med,1967,276(24):1339-1344
4[4]Kalow,W.Perspectives in pharmacogeoetics.Arch Pathol Lab Med,2001,125:77-80
5[5]Schalekamp T,Brasse BP,Roijers JF,et al.VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status:interaction betwean both genotypes affects overanticoagulation.Clin Pharmacol Ther,2006,80(1):13 -22
6[6]Mikus G,Schowel V,Drzewinska M,et al.Potent cytochrome P450 2C19 genotypc -related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.Clin Pharmacol Ther,2006,80 (2):126-135
7[7]Grossman I.Routine pharmacogenetic testing in clinical practice:dream or reality? Pharmacogenomics,2007,8(10):1449-1459
8[8]Napolitano C,Schwartz PJ,Brown AM,Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias.J Cardiovasc Electrophysiol,2000,11 (6):691 -696
9[9]Yang P,Kanki H,Drolet B,Yang T,Wei J.Allelic variants in long-QT disease genes in patients with drug-associated tarsades de pointes.Circulation,2002,105(16):1943-1948
10[10]Splawski I,Timothy KW,Tateyama M,Variant of SCN5A sodium channel implicated in risk of cardiac arthythmia.Science,2002,297 (5585):1333-1336
9Ingelman-Sundberg M,Sim SC.Pharmacogeneticbiomarkers as tools for improved drug therapy;emphasison the cytochrome P450 system. Biochemistry and Biophysics . 2010
10Rushmore TH,Kong AN.Pharmacogenomics,regulationand signaling pathways of phase I and II drug metabolizingenzymes. Current Drug Metabolism . 2002
